Trial Profile
Suppression of oral shedding of human herpesvirus 8 (HHV-8) with valganciclovir
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jul 2007
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Herpes simplex virus infections
- Focus Therapeutic Use
- 12 Nov 2006 New trial record.